<h4>Background</h4>Bevacizumab, a VEGF-A inhibitor widely used in ovarian cancer, is associated with kidney adverse effects ranging from mild proteinuria to thrombotic microangiopathy (TMA). The gene discussed is VEGFA; the disease is Genetic thrombotic microangiopathy.